Acumen Diagnostics, a medical technology company that operates two laboratories in Singapore to provide swabbing and Covid-19 polymerase chain reaction (PCR) tests services is intending to list on the Nasdaq stock exchange in New York. Furthermore, Acumen has appointed an advisors to assist with the listing evaluation and all relevant preparatory work including the selection of professional advisors and underwriting banks.
Acumen is 50% owned by Q&M Dental Group and 49% owned by Q&M’s Chinese dental business Aoxin Q&M. If this listing goes through, Acumen would be Q&M’s second spin-off, with Aoxin Q&M being its first spin-off listing on the Catalist Board of Singapore Exchange (SGX) back in 2017.
The reasons for choosing Nasdaq is because it is one of the most well-known listing platforms in the world. Nasdaq is known for its technology, innovation, and it is home to digital, biotechnology, and other cutting edge companies.
